Patents by Inventor Chloé James
Chloé James has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139870Abstract: A laser crafting apparatus for directing electromagnetic radiation toward a workpiece may include various features. For example, the laser crafting apparatus may include a material support tray that is removably supported within an internal volume of the laser crafting apparatus. Further, the apparatus may include pre-filter disposed in a ventilation pathway between a workspace region of the internal volume and an extractor fan. The laser crafting apparatus may include a laser carriage assembly that houses a laser module and the assembly may include a lens tray detachably coupled to the support structure of the laser carriage assembly. In various embodiments, the laser crafting apparatus includes a lid having a radiation attenuation layer and a fire suppression layer.Type: ApplicationFiled: March 8, 2022Publication date: May 2, 2024Applicant: Cricut, Inc.Inventors: Sterling Kingdon, Joe Martin, Andrew James Yuill, Kurt Stalsberg, Tanner Hesterman, Richard Petty, Kyle Kenneth Johnson, Devin Higgs Anderson, Muchuan Chen, Cole Chamberlain, Adam Worsham, Colter Leys, Everett Sidney Kettle, Marc Korbuly, Stephan Clark, Jesse Anderegg, Chloe Georgiades
-
Publication number: 20240101533Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.Type: ApplicationFiled: June 5, 2023Publication date: March 28, 2024Inventors: Kevin McCormack Allan, Amanda Lynn Vandehey, Gediminas Brizgys, Sachin Dhar, Ian James Doxsee, Alex Goldberg, Lars V. Heumann, Zilin Huang, Nathaniel Thomas Kadunce, Shahrokh Kazerani, Willard Lew, Vinh Xuan Ngo, Brian Michael O`Keefe, Trevor James Rainey, Benjamin James Roberts, Bing Shi, Dietrich P. Steinhuebel, Winston C. Tse, Anna Michelle Wagner, Xianghong Wang, Scott Alan Wolckenhauer, Chloe Yuyi Wong, Jennifer R. Zhang
-
Publication number: 20230157994Abstract: A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.Type: ApplicationFiled: May 5, 2021Publication date: May 25, 2023Applicants: 4LIVING BIOTECH, UNIVERSITE DE BORDEAUX, CENTRE HOSPITALIER DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE LILLEInventors: Patrick BERGER, Isabelle DUPIN, Renaud PREVEL, Chloé JAMES, Pierre-Olivier GIRODET, Keren BISMUTH, Revital RATTENBACH, Jérôme BRETON, Francois TROTTEIN, Valentin SENCIO
-
Publication number: 20220236270Abstract: Deamidation is usually viewed as a post-translational modification that sets an expiration date on proteins. Among apoptosis regulators of the Bcl-2 family, Bcl-xL shows a unique eligibility to be either singly or doubly deamidated. The inventors therefore analysed Bcl-xL deamidation state in platelets from mice models where platelets lifespan was manipulated. In parallel, the inventors compared human platelets obtained at steady state from healthy controls, to platelets newly synthesized after recovery from acute thrombocytopenia: they found that while expression levels of Asn52 monodeamidated Bcl-xL remains unchanged, Asn52Asn66 doubly-deamidated Bcl-xL is virtually absent in young platelets and accumulates in old platelets. Therefor the Asn52Asn66 doubly-deamidated Bcl-xL could be used as a reliable biomarker for determining the age of platelets.Type: ApplicationFiled: June 11, 2020Publication date: July 28, 2022Inventors: Chloé JAMES, Florian BEAUMATIN, Muriel PRIAULT
-
Publication number: 20220042016Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: September 29, 2021Publication date: February 10, 2022Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 11162100Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 6, 2020Date of Patent: November 2, 2021Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20200140863Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Publication number: 20200087403Abstract: Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neo-plasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.Type: ApplicationFiled: March 14, 2018Publication date: March 19, 2020Inventors: Chloé JAMES, Thierry COUFFINHAL, Virginie GOURDOU-LATYSZENOK, Alexandre GUY, Martine JANDROT-PERRUS
-
Patent number: 10563200Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: May 29, 2019Date of Patent: February 18, 2020Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS—SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20190323007Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: May 29, 2019Publication date: October 24, 2019Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Rescherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris-SudInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 10364430Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 27, 2014Date of Patent: July 30, 2019Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20150051263Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 27, 2014Publication date: February 19, 2015Inventors: William VAINCHENKER, Valerie UGO, Chloe JAMES, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 8637235Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: September 19, 2008Date of Patent: January 28, 2014Assignees: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite de Versailles—St Quentin en Yvelines, Universite Paris—SUDInventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20120066776Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: August 19, 2011Publication date: March 15, 2012Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Patent number: 7781199Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.Type: GrantFiled: October 26, 2005Date of Patent: August 24, 2010Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20090162849Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: September 19, 2008Publication date: June 25, 2009Inventors: William VAINCHENKER, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20080076135Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: November 2, 2007Publication date: March 27, 2008Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20060288432Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.Type: ApplicationFiled: October 26, 2005Publication date: December 21, 2006Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Patent number: D1018354Type: GrantFiled: March 9, 2021Date of Patent: March 19, 2024Assignee: TIFFANY AND COMPANYInventors: Nurit Quinters, Jessy Duval, Nathan Green, Cary James, Rachel Bassler, Chloe Shen
-
Patent number: D1019453Type: GrantFiled: March 9, 2021Date of Patent: March 26, 2024Assignee: TIFFANY AND COMPANYInventors: Nurit Quinters, Jessy Duval, Nathan Green, Cary James, Rachel Bassler, Chloe Shen